Meta-Analysis of Prophylactic Treatments Against Pneumocystis carinii Pneumonia and Toxoplasma Encephalitis in HIV-Infected Patients (Q73552583)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241108%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

meta-analysis

0 references

title

Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241108%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Meta-Analysis of Prophylactic Treatments Against Pneumocystis carinii Pneumonia and Toxoplasma Encephalitis in HIV-Infected Patients (English)

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

9 November 2024

1 reference

1 reference

1 reference

Pneumocystis carinii

1 reference

3

G H Guyatt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241108%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

H. C. Bucher

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9241108

9 November 2024

L. Griffith

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9241108

9 November 2024

G. H. Guyatt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9241108

9 November 2024

M. Opravil

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9241108

9 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9241108

9 November 2024

publication date

1 June 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241108%20AND%20SRC:MED&resulttype=core&format=json

Journal of Acquired Immune Deficiency Syndromes

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241108%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241108%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241108%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

104-114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241108%20AND%20SRC:MED&resulttype=core&format=json

Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS

4 November 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

A Controlled Study of Inhaled Pentamidine for Primary Prevention ofPneumocystis cariniiPneumonia

9 November 2024

2

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial

9 November 2024

3

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021

9 November 2024

4

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group

9 November 2024

5

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS

9 November 2024

6

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group

9 November 2024

7

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients

9 November 2024

8

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Changes in the spectrum of AIDS-defining conditions and decrease in CD4+ lymphocyte counts at AIDS manifestation in Germany from 1986 to 1991

9 November 2024

9

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group

9 November 2024

11

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

A method for assessing the quality of a randomized control trial

9 November 2024

12

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Four different regimens for prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients

9 November 2024

13

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Meta-analysis in clinical trials

9 November 2024

14

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

The statistical basis of meta-analysis

9 November 2024

15

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Journal of Acquired Immune Deficiency Syndromes

9 November 2024

16

7

457

May

1994

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Randomized study of sulfamethoxazole-trimethoprim versus aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with AIDS.

9 November 2024

17

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Patient tolerance of nebulized pentamidine or cotrimoxazole as secondary prophylaxis for Pneumocystis carinii pneumonia

9 November 2024

18

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial

9 November 2024

19

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis

9 November 2024

20

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis

9 November 2024

21

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group

9 November 2024

22

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

9 November 2024

23

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis

9 November 2024

24

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients.

9 November 2024

26

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Journal of Acquired Immune Deficiency Syndromes

9 November 2024

27

5

341

Blum

1992

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV

9 November 2024

28

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS

9 November 2024

29

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group.

9 November 2024

30

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients

9 November 2024

31

1 reference

https://api.crossref.org/works/10.1097/00042560-199706010-00002

9 November 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9241108%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference